Hemispherx Biopharma Reports Clinical Potential of Treatment for Drug-Resistant Influenza Virus - - BioPharm International

ADVERTISEMENT

Hemispherx Biopharma Reports Clinical Potential of Treatment for Drug-Resistant Influenza Virus


Hemispherx Biopharma published an article entitled “Emergence of a novel drug resistant H7N9 influenza virus: Evidence based clinical potential of a natural interferon (IFN)-αlpha for infection control and treatment” in the early online edition of Expert Review of Anti-infective Therapy, the company announced in a press release. H7N9 is a recently identified virus associated with high mortality in humans with the potential to emerge as an agent for a global pandemic. New cases of H7N9 have been recently reported in China, Hong Kong, and Taiwan. In vitro tests reported in the new article demonstrated that both oseltamivir (Tamiflu) and Alferon N have significant inhibitory effect on a neuraminidase-inhibitor sensitive H7N9 influenza virus. In contrast, Alferon N, but not Tamiflu, had an inhibitory effect on the neuraminidase-resistant Shanghai/1/H7N9 virus.

According to the peer-reviewed article, “Because of the lack of existing immunity against H7 subtype influenza viruses in the human population and the absence of a licensed commercial vaccine, antiviral drugs are critical tools for the treatment of infection with this novel H7N9. Both M2-ion channel blockers and neuraminidase inhibitors are used as antiviral drugs for influenza infections of humans. The emerging H7N9 viruses are resistant to the M2-ion channel blockers because of a S31N mutation in the M2 protein; additionally, some H7N9 isolates have gained neuraminidase R292K substitution resulting in broad resistance to neuraminidase inhibitors. In this study we report that Alferon N can inhibit wild type and 292K H7N9 viruses replication in vitro. Since Alferon N is approved for clinical use, this would allow a rapid regulatory approval process for this drug under pandemic threat.”

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here